Sprint Bioscience AB (publ) (STO: SPRINT)
Sweden
· Delayed Price · Currency is SEK 1.240
0.00 (0.00%)
Sep 11, 2024, 5:00 PM CET
Sprint Bioscience AB Company Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer.
The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Sprint Bioscience AB (publ)
| Country | Sweden |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Johan Emilsson |
Contact Details
Address: Novum Huddinge, Stockholm County 141 57 Sweden | |
| Phone | 46 84 11 44 55 |
| Website | sprintbioscience.com |
Stock Details
| Ticker Symbol | SPRINT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006343745 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johan Emilsson | Chief Executive Officer |
| Prof. Pär Nordlund | Founder |
| Dr. Martin Andersson | Co-Founder and Chief Scientific Officer |
| Dr. Kenth Hallberg | Founder and Director of Structural Chemistry |
| Mathias Skalmstad | Chief Financial Officer |
| Anne-Marie Wenthzel | Chief Business Officer |